Variables including age, gender, PS, cancer type, TNM stage, liver metastasis, multiple metastases, treatment line, combination therapy, the level of LDH, IgG, IgA, IgM, IL-6, IL-8, IL-10, TNF-α, hsCRP, ESR, PD-L1 status, MSI status, any preexisting antibody (positive or negative), ANA (positive or negative), ANA titer (≥1:160 or <160), anti-Ro52 antibody (positive or negative), and antithyroid antibody (positive or negative) were examined in LASSO regression. This evidence concerns the gene CD79A and cancer.